Royalty Pharma (RPRX) FCF Margin (2019 - 2026)
Royalty Pharma (RPRX) reported FCF Margin of 42.16% for Q1 2026, down 6255.0% on a YoY basis from 0.69% in Q1 2025, and up 180.59% sequentially from 15.03% in Q4 2025.
Royalty Pharma (RPRX) FCF Margin (2019 - 2026) Analysis & Trends
Royalty Pharma (RPRX) has 8 years of FCF Margin data on file, last reported at 42.16% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin fell 6255.0% year-over-year to 42.16%; the trailing twelve-month figure through Mar 2026 stood at 18.97% (up 661.0% YoY), and the FY2025 full-year result was 33.31%, up 2168.0% from the prior year.
- FCF Margin advanced to 42.16% in Q1 2026, from 15.03% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 104.71% in Q1 2025 to a low of 135.58% in Q3 2022.
- A 5-year average of 26.58% and a median of 42.16% in 2026 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin surged 15840 bps in 2023 and plunged 11481 bps in 2024, its largest moves.
- Tracing RPRX's FCF Margin over 5 years: stood at 56.51% in 2022, then sank by 168 bps to 38.52% in 2023, then jumped by 208 bps to 41.46% in 2024, then sank by 64 bps to 15.03% in 2025, then surged by 181 bps to 42.16% in 2026.
- Business Quant data shows RPRX's FCF Margin at 42.16% in Q1 2026, 15.03% in Q4 2025, and 42.55% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Royalty Pharma | 25.78 Bn | 28.22 Bn | - | 42.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42.16% |
| Dec 31, 2025 | 15.03% |
| Sep 30, 2025 | -42.55% |
| Jun 30, 2025 | 62.71% |
| Mar 31, 2025 | 104.71% |
| Dec 31, 2024 | 41.46% |
| Sep 30, 2024 | -86.94% |
| Jun 30, 2024 | -13.11% |
| Mar 31, 2024 | 101.86% |
| Dec 31, 2023 | -38.52% |
| Sep 30, 2023 | 22.82% |
| Jun 30, 2023 | 101.70% |
| Mar 31, 2023 | 63.18% |
| Dec 31, 2022 | 56.51% |
| Sep 30, 2022 | -135.58% |
| Jun 30, 2022 | 74.62% |
| Mar 31, 2022 | 81.88% |
| Dec 31, 2021 | 55.28% |
| Sep 30, 2021 | -147.88% |
| Jun 30, 2021 | 63.26% |